Clinical Trials
4 trialsNCT07504588 2026-06-03
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT06028932 2026-03-05
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
Phase 2 Active not recruiting
NCT04251416 2026-02-17
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Yale University
Phase 2 Active not recruiting
NCT05838521 2026-02-06
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Yale University
Phase 2 Recruiting